Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...
Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data from dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback